Social Media Monitoring Report on Vyxeos a drug by Jazz Pharmaceuticals for Acute Myeloid Leukemia (AML)
Research Study Background
Jazz Pharmaceuticals developed drug, Vyxeos (daunorubicin and cytarabine) got US FDA marketing approval on 18th Aug 2017 for adult patients with high-risk Acute Myeloid Leukemia (AML).
Vyxeos is a liposomal combination of Daunorubicin & Cytarabine which is an anthracycline topoisomerase & nucleoside metabolic inhibitor that affect regulation of gene expression & inhibits DNA polymerase. US FDA approval was based on a pivotal Phase 3 clinical trial that evaluated the efficacy and safety of Vyxeos compared to Daunorubicin & Cytarabine. Vyxeos showed significant improvement in AML with complete response rate by 38% Vs 26% on adult patients with t-AML or AML.
Vyxeos represents the first new advance chemotherapy after 40 years for adult AML patients. Jazz Pharmaceutical’s got Prior marketing authorization for Vyxeos under Priority Review Scheme by FDA, which was aimed to accelerate approval of therapies to fulfil unmet needs of patients with AML.
Sentiment Analysis on Vyxeos Drug Approval
Positive: Vyxeos approval was quoted as a Impressive breakthrough - ““Impressive…FDA has approved 3 new drugs for AML this yr vs. ZERO in past decade $NVS Rydapt $CELG AGIO IDHIFA $JAZZ $CPXX Vyxeos $PFE Mylotarg (next)”- FARIS43211 (HCP)
Negative: Some were found concerned about Vyxeos off-label use which reflected negatively on social media channels – ““Jazz Pharma unlikely to see off-label use for Vyxeos says @BioPharmInsight featuring expertise from our Greg Dombal.”- HALLORANCONSULT (Unidentified Individual)
Neutral: Majority of healthcare practitioners and patients were either neutral or positive about the approval, efficacy and found sharing the information on social media platform- “Vyxeos combines two commonly used chemotherapies into a single formulation that may help some patients live longer.“- dhoustonsmith (Patient)